|
TECHNOLOGY
BRIEF – Trioxolane
Products
developed by Dr. Stephen Herman, M. D.
This
newly patented medicinal agent "TRIOXOLANE" was developed to address
the worldwide threat of viral epidemic as well as the increasing
occurrence of antibiotic resistant organisms throughout the world.
The
most broadly successful treatment for human disease is provided
by our own immune system. This includes all infections, growth of
abnormal tissues, and autoimmune diseases. An intact and functioning
immune system maintains a disease free state while suppressed or
dysfunctional immune system leaves us susceptible to a wide range
of maladies almost without restriction.
Common
denominators created by the immune system are sought for the treatment
to disease rather than diverse chemical substances unrelated to
human evolution. After fourteen years of research, Immune
Technologies is honored to announce the development of an extraordinary
breakthrough medicinal agent.
This
patented agent is a 1,2,4 -Trioxolane designated as "Alphamir."
Alphamir is a high- energy bio-oxidant that mimics and augments
the natural production of bio-oxidants by the human immune system
and white blood cells.
Alphamir
is non-toxic and microorganisms cannot develop resistance. It is
effective in a broad spectrum of applications including autoimmune
disease, arthritis, viral disease, infections, burns and many dermatological
conditions. Alphamir requires no
monitoring or training for its distribution and will be available
for a small fraction of the cost of present treatments.
Multiple
clinical trials have been completed and Alphamir
has been registered and approved for sale by the Ministry of Health
of Kenya (FDA) Africa for use in HIV/AIDS
and Arthritis. This approval, May 24, 2001, is valid in twenty eight
African Countries.
Protocols
are now ready to begin trials at the Kenya
Medical Research Institute for our contraceptive vaginal
gel, Prophamir, which
will prevent the transmission of AIDS.
See
our business plan for other diseases tested. We are prepared to
initiate wide scale treatments in Africa immediately upon funding.
|
